References
- 1. Solano-Gallego L, Llull J, Ramos G, Riera C, Arboix M, Alberola J, Ferrer L: The Ibizian hound presents a predominantly cellular immune response against natural Leishmania infection. Vet Parasitol 2000, 90:37-45.10.1016/S0304-4017(00)00223-5
- 2. Sideris V, Papadopoulou G, Dotsika E, Karagouni E: Asymptomatic canine leishmaniasis in Greater Athens area, Greece. Eur J of Epidemiol 1999, 15:271-276.10.1023/A:1007526401175
- 3. Baneth G, Koutinas AF, Solano-Gallego L, Bourdeau P, Ferrer L: Canine leishmaniosis - new concepts and insights on an expanding zoonosis: part one. Trends Parasitol 2008, 24:324-330.10.1016/j.pt.2008.04.001
- 4. Barbieri CL: Immunology of canine leishmaniasis. Parasite Immunol 2008; 28:329-337.
- 5. Quinnell RJ, Kennedy LJ, Barnes A, Courtenay O, Dye C, Garcez LM, Shaw MA, Carter SD, Thomson W, Ollier WE: Susceptibility to visceral leishmaniasis in the domestic dog is associated with MHC class II polymorphism. Immunogenetics 2003, 55:23-28.10.1007/s00251-003-0545-1
- 6. Symeonidou I, Hatzistilianou M, Papadopoulos E, Dovas CI, Karagouni E, Pappa S, Pantzartzi C, Kourelis A, Frydas S: Susceptibility and resistance to canine leishmaniosis is associated to polymorphisms of the canine TNF-α gene. Eur J of Inflamm 2011, Vol. 9:23-29.10.1177/1721727X1100900104
- 7. Canonne-Hergaux F, Gruenheid S, Govoni G, Gros P: The SLC11A1 protein and its role in resistance to infection and macrophage function. Proc Assoc Am Physicians 1999, 111:283-289.10.1046/j.1525-1381.1999.99236.x
- 8. Blackwell JM, Searle S, Mohamed H, White JK: Divalent cation transport and susceptibility to infectious and autoimmune disease: continuation of the Ity/Lsh/Bcg/SLC11A1/Nramp1 gene story. Immunol Lett 2003, 85:197-203.10.1016/S0165-2478(02)00231-6
- 9. Rojas M, Olivier M, Gros P, Barrera LF, Garcia LF: TNF-alpha and IL-10 modulate the induction of apoptosis by virulent Mycobacterium tuberculosis in murine macrophages. J Immunol 1999, 162:6122-6131.10.4049/jimmunol.162.10.6122
- 10. Govoni G, Gros P: Macrophage SLC11A1 and its role in resistance to microbial infections. Inflamm Res 1998, 47:277-284.10.1007/s0001100503309719491
- 11. Huynh C, Andrews NW: Iron acquisition within host cells and the pathogenicity of Leishmania. Cell Microbiol 2008, 10:293-300.10.1111/j.1462-5822.2007.01095.x236699818070118
- 12. Altet L, Francino O, Solano-Gallego L, Renier C, Sanchez A: Mapping and sequencing of the canine SLC11A1 gene and identification of mutations in leishmaniasis-susceptible dogs. Infect Immun 2002, 70:2763-2771.10.1128/IAI.70.6.2763-2771.200212796512010961
- 13. Sanchez-Robert E, Altet L, Sanchez A, Francino O: Polymorphism of SLC11A1 (Nramp1) gene and canine leishmaniasis in a case-control study. J Hered 2005, 96:755-758.10.1093/jhered/esi11116251521
- 14. Sanchez-Robert E, Altet L, Utzet-Sadurni M, Giger U, Sanchez A, Francino O: SLC11A1 (formerly Nramp1) and susceptibility to canine visceral leishmaniasis. Vet Res 2008, 39:36.10.1051/vetres:2008013
- 15. Kouam MK, Diakou A, Kantzoura V, Papadopoulos E, Gajadhar AA, Theodoropoulos G: A seroepidemiological study of exposure to Toxoplasma, Leishmania, Echinococcus and Trichinella in equids in Greece and analysis of risk factors. Vet Parasitol 2010, 170: 170–175.10.1016/j.vetpar.2010.02.00420197215
- 16. Leclercq V, Lebastard M, Belkaid Y, Louis J, Milon G: The outcome of the parasitic process initiated by Leishmania infantum in laboratory mice: a tissue-dependent pattern controlled by the Lsh and MHC loci. J Immunol 1996, 157:4537-4545.10.4049/jimmunol.157.10.4537
- 17. Searle S, Blackwell JM: Evidence for a functional repeat polymorphism in the promoter of the human SLC11A1 gene that correlates with autoimmune versus infectious disease susceptibility. J Med Genet 1999, 36:295-299.10.1136/jmg.36.4.295
- 18. El-SafiS, Kheir MM, Bucheton B, Argiro L, Abel L, Dereure J, Dedet JP, Dessein A: Genes and environment in susceptibility to visceral leishmaniasis. C R Biol 2006, 329:863-870.10.1016/j.crvi.2006.07.00717067929
- 19. Ejghal R, Hida M, Idrissi ML, Hessni AE, Lemrani M: SLC11A1 polymorphisms and susceptibility to visceral leishmaniasis in Moroccan patients. Acta Trop 2014, 140130-136.10.1016/j.actatropica.2014.08.01325151047
- 20. Hernández-Rivera MP, Ramírez-Ramírez A, Chiñas-Pérez A, Monroy-Ostria A, Cancino-Díaz ME. Hernández-Montes: NRAMP1 Polymorphisms like Susceptibility Marker in Mexican Focus of Cutaneous Leishmaniasis. Biomed Res Int Vol 2016, Article ID 7951285.10.1155/2016/7951285508833027830154
- 21. Fattahi-Dolatabadi M, Mousavi T, Mohammadi-Barzelighi H, Irian S, Bakhshi B, Nilforoushzadeh MA, Shirani-Bidabadi L, Hariri MM, Ansari N, Akbari NJ: NRAMP1 gene polymorphisms and cutaneous leishmaniasis: An evaluation on host susceptibility and treatment outcome. J Vector Borne Dis 2016, 53:257-263.
- 22. Bueno R, Carvalho Neta AV, Xavier MN, Oliveira RG, Diniz SA, Melo MN, Santos RL: cDNA sequencing and expression of SLC11A1 (Nramp1) in dogs phenotypically resistant or susceptible to visceral leishmaniasis. Vet Immunol Immunopathol 2009, 127:332-339.10.1016/j.vetimm.2008.10.33519084282
- 23. Soo SS, Villarreal-Ramos B, Anjam Khan CM, Hormaeche CE, Blackwell JM: Genetic control of immune response to recombinant antigens carried by an attenuated Salmonella typhimurium vaccine strain: SLC11A1 influences T-helper subset responses and protection against leishmanial challenge. Infect Immun 1998, 66:1910-1917.10.1128/IAI.66.5.1910-1917.19981081439573069
- 24. Boonstra A, Rajsbaum R, Holman M, Marques R, Asselin-Paturel C, Pereira JP, Bates EE, Akira S, Vieira P, Liu YJ, Trinchieri G, O’Garra A: Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. J Immunol 2006, 177:7551-7558.10.4049/jimmunol.177.11.755117114424
- 25. O’Garra A, Murphy KM: From IL-10 to IL-12: how pathogens and their products stimulate APCs to induce T(H)1 development. Nat Immunol 2009, 10:929-932.10.1038/ni0909-92919692989
- 26. Stober CB, Brode S, White JK, Popoff JF, Blackwell JM: SLC11A1, formerly Nramp1, is expressed in dendritic cells and influences major histocompatibility complex class II expression and antigen-presenting cell function. Infect Immun 2007, 75:5059-5067.10.1128/IAI.00153-07204452917620357
- 27. Lang T, Prina E, Sibthorpe D, Blackwell JM: SLC11A1 transfection transfers Ity/Lsh/Bcg-related pleiotropic effects on macrophage activation: influence on antigen processing and presentation. Infect Immun 1997, 65:380-386.10.1128/iai.65.2.380-386.19971746069009286
- 28. Sypek JP, Chung CL, Mayor SE, Subramanyam JM, Goldman SJ, Sieburth DS, Wolf SF, Schaub RG: Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 1993, 177:1797-1802.10.1084/jem.177.6.179721910368098733
- 29. Wojciechowski W, DeSanctis J, Skamene E, Radzioch D: Attenuation of MHC class II expression in macrophages infected with Mycobacterium bovis bacillus Calmette-Guerin involves class II transactivator and depends on the Nramp1 gene. J Immunol 1999, 163:2688-2696.10.4049/jimmunol.163.5.2688
- 30. Georges AB, Benayoun BA, Caburet S, Veitia RA: Generic binding sites, generic DNA binding domains: where does specific promoter recognition come from? FASEB J. 2010; 24:346-56.10.1096/fj.09-14211719762556